Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO)

NCT05662241 is registered in ClinicalTrials.gov with Zenas BioPharma (USA), LLC as lead sponsor.

NCT NCT05662241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05662241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients With IgG4-Related Disease (INDIGO)
Lead sponsor
Zenas BioPharma (USA), LLC
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 9, 2023
Completion date
February 15, 2029
Enrollment
194 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

igg4 related disease